title: Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio.
authors: Alberto J
authors: AJ
authors: Espay
authors: Jennifer E
authors: JE
authors: Vaughan
authors: Rakesh
authors: R
authors: Shukla
authors: Maureen
authors: M
authors: Gartner
authors: Alok
authors: A
authors: Sahay
authors: Fredy J
authors: FJ
authors: Revilla
authors: Andrew P
authors: AP
authors: Duker
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology; D004576:Electromyography / Q000379:methods; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D008297:Male; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D009465:Neuromuscular Agents; D007980:Levodopa; D019274:Botulinum Toxins, Type A